Another case report on CRP apheresis was published in the journal Blood purification über die CRP-Aphererse veröffentlicht.

The application of PentraSorb® CRP after myocardial infarction was once again described as very safe and effective in a new case report. The selective CRP apheresis reduced the CRP concentration of the heart attack patient by 72% in the blood and did not cause any side effects.